|Last Price$94.98||Day Change (%)-0.73%|
|Open Price$95.34||Day Change ($)-0.70|
|Day Range94.85–96.76||52-Week Range82.50–167.92|
As of Tue 9/27/2016 2:15:00 PM | USD
Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets
UPDATE: U.S. stocks rebound after interest-rate worries spark selloff
MARKET SNAPSHOT: Stocks Extend Gains, End Higher After Brainard Offers Dovish Tone
UPDATE: Stocks extend gains, end higher after Brainard offers dovish tone
Activist investor Starboard urges drugmaker Perrigo to refocus business
The continuing U.S. stock market rally has diminished the number and similarity of purchases across these top managers.
Recent deals have been driven more by tax strategies than therapeutic synergies.
Favorable conditions are in place for merger-arbitrage ETFs, including increasing M&A activity and the likelihood of higher interest rates.